Fecal microbiota transplant promotes response in immunotherapy-refractory melanoma patients-Reference-Cited by-同舟云学术

Fecal microbiota transplant promotes response in immunotherapy-refractory melanoma patients

Published:2021-02-05 Issue:6529 Volume:371 Page:602-609
ISSN:0036-8075
Container-title:Science
language:en
Short-container-title:Science

Author:

Baruch Erez N.¹²^ORCID,Youngster Ilan³⁴^ORCID,Ben-Betzalel Guy¹,Ortenberg Rona¹^ORCID,Lahat Adi⁵,Katz Lior⁶,Adler Katerina⁷^ORCID,Dick-Necula Daniela⁸,Raskin Stephen⁴⁹^ORCID,Bloch Naamah¹⁰,Rotin Daniil⁸^ORCID,Anafi Liat⁸,Avivi Camila⁸,Melnichenko Jenny¹^ORCID,Steinberg-Silman Yael¹^ORCID,Mamtani Ronac¹¹,Harati Hagit¹^ORCID,Asher Nethanel¹^ORCID,Shapira-Frommer Ronnie¹^ORCID,Brosh-Nissimov Tal¹²,Eshet Yael⁴⁸¹³^ORCID,Ben-Simon Shira¹⁰,Ziv Oren¹⁰,Khan Md Abdul Wadud¹⁴^ORCID,Amit Moran¹⁵,Ajami Nadim J.¹⁴^ORCID,Barshack Iris⁴⁸,Schachter Jacob¹⁴,Wargo Jennifer A.¹⁴¹⁶^ORCID,Koren Omry¹⁰^ORCID,Markel Gal¹²¹⁷^ORCID,Boursi Ben⁴¹⁸¹⁹^ORCID

Affiliation:

1. The Ella Lemelbaum Institute for Immuno-Oncology, Sheba Medical Center, Tel-HaShomer, Israel.

2. Department of Clinical Immunology and Microbiology, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.

3. Pediatric Division and the Microbiome Research Center, Shamir (Assaf Harofeh) Medical Center, Be’er Ya’akov, Israel.

4. School of Medicine, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.

5. Department of Gastroenterology, Sheba Medical Center, Tel HaShomer, Israel.

6. Department of Gastroenterology, Hadassah Medical Center, Jerusalem, Israel.

7. Department of Mathematics, Bar Ilan University, Ramat Gan, Israel.

8. Institute of Pathology, Sheba Medical Center, Tel-HaShomer, Israel.

9. Radiological Institute, Sheba Medical Center, Tel HaShomer, Israel.

10. Azrieli Faculty of Medicine, Bar Ilan University, Safed, Israel.

11. Division of Hematology and Oncology, University of Pennsylvania, Philadelphia, PA, USA.

12. Infectious Diseases Unit, Assuta Ashdod University Hospital, Ashdod, Israel.

13. Department of Nuclear Medicine, Sheba Medical Center, Tel HaShomer, Israel.

14. Program for Innovative Microbiome and Translational Research, Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

15. Department of Head and Neck Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

16. Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

17. Talpiot Medical Leadership Program, Sheba Medical Center, Tel HaShomer, Israel.

18. Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania, Philadelphia, PA, USA.

19. Department of Oncology, Sheba Medical Center, Tel HaShomer, Israel.

Abstract

New fecal microbiota for cancer patients The composition of the gut microbiome influences the response of cancer patients to immunotherapies. Baruch et al. and Davar et al. report first-in-human clinical trials to test whether fecal microbiota transplantation (FMT) can affect how metastatic melanoma patients respond to anti–PD-1 immunotherapy (see the Perspective by Woelk and Snyder). Both studies observed evidence of clinical benefit in a subset of treated patients. This included increased abundance of taxa previously shown to be associated with response to anti–PD-1, increased CD8 + T cell activation, and decreased frequency of interleukin-8–expressing myeloid cells, which are involved in immunosuppression. These studies provide proof-of-concept evidence for the ability of FMT to affect immunotherapy response in cancer patients. Science , this issue p. 602 , p. 595 ; see also p. 573

Publisher

American Association for the Advancement of Science (AAAS)

Subject

Multidisciplinary

Reference64 articles.

1. Survival Outcomes in Patients With Previously Untreated BRAF Wild-Type Advanced Melanoma Treated With Nivolumab Therapy

2. Gut microbiome modulates response to anti–PD-1 immunotherapy in melanoma patients

3. The commensal microbiome is associated with anti–PD-1 efficacy in metastatic melanoma patients

4. Gut microbiome influences efficacy of PD-1–based immunotherapy against epithelial tumors

5. Role of the Microbiota in Immunity and Inflammation

Cited by 926 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The effect of immunotherapy PD-1 blockade on acute bone cancer pain: Insights from transcriptomic and microbiomic profiling;International Immunopharmacology;2024-12

2. Immune checkpoint inhibitors rechallenge in non-small cell lung cancer: Current evidence and future directions;Cancer Letters;2024-11

3. Reuterin promotes pyroptosis in hepatocellular cancer cells through mtDNA-mediated STING activation and caspase 8 expression;Cancer Letters;2024-10

4. Microbiome and Immunotherapy for Melanoma;Hematology/Oncology Clinics of North America;2024-10

5. Gut microbiota and clinical response to immune checkpoint inhibitor therapy in patients with advanced cancer;Biomedical Journal;2024-10